Invigor Medical vs Next Vial
Two GLP-1 desks, one scoreboard. We put Invigor Medical and Next Vial head-to-head on the published Brief Score — the same six factors, scored the same way.
Invigor Medical
The verdict
Invigor Medical takes this head-to-head.
Invigor Medical scores 88 to 66 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.
That doesn't make Next Vial a bad call — it's best for people seeking compounded glp-1 care with legitscript certification and a named pharmacy partner. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Invigor Medical | Next Vial | |
|---|---|---|
| Brief Score | 88/100 (B+) | 66/100 (C) |
| Semaglutide | $199/mo | From $250/mo (compounded) |
| Tirzepatide | $339/mo | Not disclosed |
| Coverage | Not disclosed | 49 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.
Next Vial: New to the tracker on 1 August 2026. The published line reads From $250/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.